CN111629756A - 大麻素在治疗与Lennox-Gastaut综合征相关的癫痫发作中的用途 - Google Patents

大麻素在治疗与Lennox-Gastaut综合征相关的癫痫发作中的用途 Download PDF

Info

Publication number
CN111629756A
CN111629756A CN201880080175.4A CN201880080175A CN111629756A CN 111629756 A CN111629756 A CN 111629756A CN 201880080175 A CN201880080175 A CN 201880080175A CN 111629756 A CN111629756 A CN 111629756A
Authority
CN
China
Prior art keywords
cbd
patients
treatment
cannabidiol
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880080175.4A
Other languages
English (en)
Chinese (zh)
Inventor
杰弗里·盖伊
沃尔克·纳珀兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiwei Research Co ltd
Original Assignee
Jiwei Research Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60788456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111629756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiwei Research Co ltd filed Critical Jiwei Research Co ltd
Publication of CN111629756A publication Critical patent/CN111629756A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201880080175.4A 2017-11-15 2018-11-15 大麻素在治疗与Lennox-Gastaut综合征相关的癫痫发作中的用途 Pending CN111629756A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718862.4 2017-11-15
GB1718862.4A GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy
PCT/GB2018/053315 WO2019097238A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome

Publications (1)

Publication Number Publication Date
CN111629756A true CN111629756A (zh) 2020-09-04

Family

ID=60788456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880080175.4A Pending CN111629756A (zh) 2017-11-15 2018-11-15 大麻素在治疗与Lennox-Gastaut综合征相关的癫痫发作中的用途

Country Status (16)

Country Link
US (1) US20210169824A1 (https=)
EP (2) EP4487860A3 (https=)
JP (2) JP7391019B2 (https=)
KR (1) KR102786614B1 (https=)
CN (1) CN111629756A (https=)
AU (2) AU2018366443A1 (https=)
BR (1) BR112020009508A2 (https=)
CA (1) CA3082433A1 (https=)
DK (1) DK3710058T3 (https=)
ES (1) ES2991947T3 (https=)
FI (1) FI3710058T3 (https=)
GB (1) GB2568471B (https=)
IL (1) IL274633A (https=)
MX (2) MX2020005147A (https=)
RU (1) RU2020119390A (https=)
WO (1) WO2019097238A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR102891881B1 (ko) 2020-07-16 2025-11-26 주식회사 엘지에너지솔루션 듀얼 슬롯 다이 코터
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597280A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
WO2023060024A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEVINSKY O, MARSH E, FRIEDMAN D, ET AL.: "Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial", 《THE LANCET NEUROLOGY》 *

Also Published As

Publication number Publication date
WO2019097238A1 (en) 2019-05-23
DK3710058T3 (da) 2024-11-04
EP4487860A2 (en) 2025-01-08
AU2018366443A1 (en) 2020-06-11
JP2021502992A (ja) 2021-02-04
US20210169824A1 (en) 2021-06-10
MX2023012352A (es) 2023-10-31
GB201718862D0 (en) 2017-12-27
RU2020119390A3 (https=) 2021-12-15
KR102786614B1 (ko) 2025-03-26
JP2023168448A (ja) 2023-11-24
AU2024216397B2 (en) 2026-03-05
JP7723711B2 (ja) 2025-08-14
BR112020009508A2 (pt) 2020-10-13
EP3710058B1 (en) 2024-10-09
EP3710058A1 (en) 2020-09-23
FI3710058T3 (fi) 2024-11-11
IL274633A (en) 2020-06-30
ES2991947T3 (es) 2024-12-05
GB2568471A (en) 2019-05-22
NZ764569A (en) 2024-11-29
EP4487860A3 (en) 2025-04-02
KR20200088356A (ko) 2020-07-22
RU2020119390A (ru) 2021-12-15
GB2568471B (en) 2022-04-13
CA3082433A1 (en) 2020-05-15
AU2024216397A1 (en) 2024-09-19
JP7391019B2 (ja) 2023-12-04
MX2020005147A (es) 2020-08-20

Similar Documents

Publication Publication Date Title
CN111629756A (zh) 大麻素在治疗与Lennox-Gastaut综合征相关的癫痫发作中的用途
JP7712079B2 (ja) てんかんの処置におけるカンナビノイドの使用
JP7256186B2 (ja) てんかんの治療におけるカンナビノイドの使用
US11311498B2 (en) Use of cannabinoids in the treatment of epilepsy
CN113423396A (zh) 大麻素在治疗癫痫中的用途
HK40040845B (en) Use of cannabinoids in the treatment of epilepsy
HK40040845A (en) Use of cannabinoids in the treatment of epilepsy
Baizabal-Carvallo et al. 5. Dopamine depleting agents
Burr et al. Dravet Syndrome: Early Diagnosis and Emerging Therapies
Porcelli et al. P. 2. e. 025 Bipolar depression: quetiapine extended release effectiveness

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Sheffield, Kent, UK

Applicant after: Jazz Pharmaceutical Research UK Ltd.

Address before: Cambridge County, England

Applicant before: Jiwei Research Co.,Ltd.

Country or region before: Britain

CB02 Change of applicant information